0001000228-24-000054 | 10-Q | XBRL Viewer

Print Document

Basis of Presentation	6 Months Ended
Basis of Presentation	Jun. 29, 2024
Basis of Presentation [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation Our condensed consolidated financial statements include the accounts of Henry Schein, Inc., and all of our controlled subsidiaries (“we”, “us” and “our”). All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates for which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications, individually and in the aggregate, did not have a material impact on our condensed consolidated financial condition, results of operations or cash flows. Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 30, 2023 and with the information contained in our other publicly- available filings with the Securities and Exchange Commission. The condensed consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the three and six months ended June 29, 2024 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 28, 2024. Our condensed consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a VIE because we are its primary beneficiary, as we have the power to direct activities that most significantly affect its economic performance and have the obligation to absorb the majority of its losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The VIE’s creditors have recourse to us for losses on these trade accounts receivable. At June 29, 2024 and December 30, 2023, certain trade accounts receivable that can only be used to settle obligations of this VIE were $ 330 million and $ 284 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were $ 195 million and $ 210 million, respectively.

Plans of Restructuring	6 Months Ended
Plans of Restructuring	Jun. 29, 2024
Plans of Restructuring [Abstract]
Plans of Restructuring	Note 10 – Plans of Restructuring On August 1, 2022, we committed to a restructuring plan (the “2022 Plan”) focused on funding the priorities of the BOLD+1 strategic plan, streamlining operations and other initiatives to increase efficiency. The 2022 Plan has been completed as of July 31, 2024. We expect to record restructuring charges of $ 12 million related to the 2022 Plan during the remainder of 2024. On August 6, 2024, we committed to a new restructuring plan (the “2024 Plan”) to integrate recent acquisitions, right-size operations and further increase efficiencies. We expect to record restructuring charges associated with the 2024 Plan during the second half of 2024 and in 2025, however an estimate of the amount of these charges has not yet been determined. During the three months ended June 29, 2024, and July 1, 2023, in connection with our 2022 Plan, we recorded restructuring costs of $ 15 million and $ 18 million, respectively. During the six months ended June 29, 2024, and July 1, 2023, we recorded restructuring costs of $ 25 million and $ 48 million, respectively. The restructuring costs for these periods primarily related to severance and employee-related costs, accelerated amortization of right-of-use lease assets and fixed assets, and other lease exit costs. Restructuring costs recorded for the three and six months ended June 29, 2024 and July 1, 2023, consisted of the following: Three Months Ended June 29, 2024 Six Months Ended June 29, 2024 Health Care Distribution Technology and Value- Added Services Total Health Care Distribution Technology and Value- Added Services Total Severance and employee-related costs $ 8 $ 1 $ 9 $ 14 $ 2 $ 16 Accelerated depreciation and amortization 5 - 5 6 - 6 Exit and other related costs 1 - 1 3 - 3 Total restructuring costs $ 14 $ 1 $ 15 $ 23 $ 2 $ 25 Three Months Ended July 1, 2023 Six Months Ended July 1, 2023 Health Care Distribution Technology and Value- Added Services Total Health Care Distribution Technology and Value- Added Services Total Severance and employee-related costs $ 13 $ 1 $ 14 $ 30 $ 4 $ 34 Accelerated depreciation and amortization 2 1 3 9 1 10 Exit and other related costs 1 - 1 2 1 3 Loss on disposal of a business - - - 1 - 1 Total restructuring costs $ 16 $ 2 $ 18 $ 42 $ 6 $ 48 The following table summarizes, by reportable segment, the activity related to the liabilities associated with our restructuring initiatives for the six months ended June 29, 2024. The remaining accrued balance of restructuring costs as of June 29, 2024, which primarily relates to severance and employee-related costs, is included in accrued expenses: other within our condensed consolidated balance sheets. Liabilities related to exited leased facilities are recorded within our current and non-current operating lease liabilities within our condensed consolidated balance sheets. Technology and Health Care Value-Added Distribution Services Total Balance, December 30, 2023 $ 22 $ 1 $ 23 Restructuring costs 23 2 25 Non-cash accelerated depreciation and amortization (6) - (6) Cash payments and other adjustments (18) (3) (21) Balance, June 29, 2024 $ 21 $ - $ 21

Plans of Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Dec. 28, 2024	Jun. 29, 2024	Jul. 01, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 15	$ 18		$ 25	$ 48
Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$ 12

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Net Sales from Contracts with Customers - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023	Dec. 31, 2022
Net Sales from Contracts with Customers [Abstract]
Contract with Customer, Liability, Current	$ 77		$ 89	$ 86
Contract with Customer, Liability, Noncurrent	8		$ 9	$ 8
Contract with Customer, Liability, Revenue Recognized	$ 55	$ 56

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions

Jun. 29, 2024

Dec. 30, 2023

Current assets:

Cash and cash equivalents

$ 138

$ 171

Accounts receivable, net of allowance for credit losses of $82 and $83

^[1]

1,559

1,863

Inventories, net of reserves of $145 and $192

1,657

1,815

Prepaid expenses and other

587

639

Total current assets

3,941

4,488

Property and equipment, net

518

498

Operating lease right-of-use assets

304

325

Goodwill

3,905

3,875

Other intangibles, net

1,081

916

Investments and other

502

471

Total assets

10,251

10,573

Current liabilities:

Accounts payable

867

1,020

Bank credit lines

505

264

Current maturities of long-term debt

106

150

Operating lease liabilities

Accrued expenses:

Payroll and related

279

332

Taxes

150

137

Other

567

700

Total current liabilities

2,549

2,683

Long-term debt

^[1]

1,891

1,937

Deferred income taxes

115

Operating lease liabilities

261

310

Other liabilities

431

436

Total liabilities

5,247

5,420

Redeemable noncontrolling interests

856

864

Commitments and contingencies

Stockholders' equity:

Preferred stock, $0.01 par value, 1,000,000 shares authorized, none outstanding

Common stock, $0.01 par value, 480,000,000 shares authorized,127,080,545 outstanding on June 29, 2024 and 129,247,765 outstanding on December 30, 2023

Additional paid-in capital

Retained earnings

3,803

3,860

Accumulated other comprehensive loss

(292)

(206)

Total Henry Schein, Inc. stockholders' equity

3,512

3,655

Noncontrolling interests

636

634

Total stockholders' equity

4,148

4,289

Total liabilities, redeemable noncontrolling interests and stockholders' equity

$ 10,251

$ 10,573

[1]	Amounts presented include balances held by our consolidated variable interest entity (“VIE”). At June 29, 2024 and December 30, 2023, includes trade accounts receivable of $ 330 million and $ 284 million, respectively, and long-term debt of $ 195 million and $ 210 million, respectively.

Legal Proceedings - Narrative (Details) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
Legal Proceedings - Narrative (Details) $ in Millions	Jun. 29, 2024 USD ($) claims	Jul. 01, 2023 USD ($)	Jun. 29, 2024 USD ($) claims	Jul. 01, 2023 USD ($)	Dec. 30, 2023 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues	$ 3,136	$ 3,100	$ 6,308	$ 6,160
Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Pending Claims, Number \| claims	175		175
Actions Consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Maximum sales of opioids in North America during the year, percentage					0.40%
Actions Consolidated in the MultiDistrict Litigation [Member] \| Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues					$ 12,300
Other Hospitals Located throughout Florida [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plaintiffs			25

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Stock-Based Compensation	6 Months Ended
Stock-Based Compensation	Jun. 29, 2024
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 12 – Stock-Based Compensation Stock-based awards are provided to certain employees under our 2024 Stock Incentive Plan (formerly known as our 2020 Stock Incentive Plan) and to non-employee directors under our 2023 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors (the “Compensation Committee”). Historically, equity-based awards to our employees have been granted solely in the form of time-based and performance-based restricted stock units (“RSUs”) with the exception of our 2021 plan year in which non-qualified stock options were issued in place of performance-based RSUs and in 2022, when we granted time-based and performance-based RSUs, as well as non-qualified stock options. Starting with our 2023 plan year, we returned to granting our employees equity-based awards solely in the form of time-based and performance-based RSUs. Our non-employee directors receive equity-based awards solely in the form of time- based RSUs. RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common stock is delivered on or following satisfaction of vesting conditions. We issue RSUs to employees that primarily vest (i) solely based on the recipient’s continued service over time, primarily with four -year cliff vesting and/or (ii) based on achieving specified performance measurements and the recipient’s continued service over time, primarily with three -year cliff vesting. RSUs granted to our non-employee directors primarily include 12 -month cliff vesting. For these RSUs, we recognize the cost as compensation expense on a straight-line basis. For all RSUs, we estimate the fair value based on our closing stock price on the grant date. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant. Each of the Plans provide for certain adjustments to the performance measurement in connection with awards under the Plans. With respect to the performance-based RSUs granted under our 2024 Stock Incentive Plan, such performance measurement adjustments relate to significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), differences in budgeted average outstanding shares (other than those resulting from capital transactions referred to above), restructuring costs, if any, amortization expense recorded for acquisition-related intangible assets (solely with respect to performance-based RSUs granted in the 2023 and 2024 plan years), certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets, foreign exchange fluctuations, the financial impact either positive or negative, of the difference in projected earnings generated by COVID-19 test kits (solely with respect to performance-based RSUs granted in the 2022 and 2023 plan years) and impairment charges (solely with respect to performance-based RSUs granted in the 2023 and 2024 plan years), and unforeseen events or circumstances affecting us. Over the performance period, the number of RSUs that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense is based on our actual performance metrics as defined under the 2024 Stock Incentive Plan. Stock options are awards that allow the recipient to purchase shares of our common stock after vesting at a fixed price set at the time of grant. Stock options were granted at an exercise price equal to our closing stock price on the date of grant. Stock options issued in 2021 and 2022 vest one-third per year based on the recipient’s continued service, subject to the terms and conditions of the 2020 Stock Incentive Plan, are fully vested three years from the grant date and have a contractual term of ten years from the grant date, subject to earlier termination of term and term acceleration upon certain events. Compensation expense for stock options is recognized using a graded vesting method. We estimate grant date fair value of stock options using the Black-Scholes valuation model. During the six months ended June 29, 2024, we did no t grant any stock options. Our condensed consolidated statements of income reflect pre-tax share-based compensation expense of $ 12 million, and $ 20 million for the three and six months ended June 29, 2024, respectively. For the three and six months ended July 1, 2023, we recorded pre-tax share-based compensation expense of $ 14 million, and $ 24 million. Total unrecognized compensation cost related to unvested awards as of June 29, 2024 was $ 104 million, which is expected to be recognized over a weighted-average period of approximately 2.6 years. Our condensed consolidated statements of cash flows present our stock-based compensation expense as a reconciling adjustment between net income and net cash provided by operating activities for all periods presented. There were no cash benefits associated with tax deductions in excess of recognized compensation for the six months ended June 29, 2024 and July 1, 2023. We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our stock, historical volatility of our stock and other factors. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant that most closely aligns to the expected life of options. The six - year expected life of the options was determined using the simplified method for estimating the expected term as permitted under Staff Accounting Bulletin Topic 14. The following table summarizes the stock option activity for the six months ended June 29, 2024: Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Intrinsic Shares Price Life (in years) Value Outstanding at beginning of period 1,078,459 $ 71.46 Granted - - Exercised (44,750) 62.71 Forfeited (4,608) 84.60 Outstanding at end of period 1,029,101 $ 71.78 7.1 $ 1 Options exercisable at end of period 889,060 $ 69.71 Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Expected to vest 140,041 $ 84.94 7.7 $ - The following tables summarize the activity of our unvested RSUs for the six months ended June 29, 2024: Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Weighted Average Intrinsic Average Intrinsic Grant Date Fair Value Grant Date Fair Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,655,393 $ 70.34 208,742 $ 78.02 Granted 461,798 75.88 408,681 76.31 Vested (321,460) 62.79 (8,262) 66.53 Forfeited (59,283) 77.31 (35,527) 80.55 Outstanding at end of period 1,736,448 $ 72.99 $ 64.10 573,634 $ 75.78 $ 64.10

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (47)		$ (47)		$ (32)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	(1)		(1)		(1)
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment	(289)		(289)		(188)
Unrealized gain (loss) from hedging activities	2		2		(13)
Pension adjustment loss	(5)		(5)		(5)
Accumulated other comprehensive loss	(292)		(292)		(206)
Total Accumulated other comprehensive loss	(340)		(340)		$ (239)
Components of Comprehensive Income
Net Income (loss)	105	$ 148	203	$ 276
Foreign currency translation gain (loss)	(62)	3	(116)	28
Tax effect	0	0	0	0
Foreign currency translation gain (loss)	(62)	3	(116)	28
Unrealized gain (loss) from hedging activities	6	(2)	21	(6)
Tax effect	(2)	1	(6)	2
Unrealized gain (loss) from hedging activities	4	(1)	15	(4)
Comprehensive income	$ 47	$ 150	$ 102	$ 300

Significant Accounting Policies and Recently Issued Accounting Standards	6 Months Ended
	Jun. 29, 2024
Significant Accounting Policies and Recently Issued Accounting Standards [Abstract]
Significant Accounting Policies and Recently Issued Accounting Standards	Note 2 – Significant Accounting Policies and Recently Issued Accounting Standards Significant Accounting Policies There have been no material changes in our significant accounting policies during the three and six months ended June 29, 2024, as compared to the significant accounting policies described in Item 8 of our Annual Report on Form 10-K for the year ended December 30, 2023. Recently Issued Accounting Standards In March 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-01, “ Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, ” which clarifies how to determine whether a profit interest and similar awards should be accounted for as a share-based payment arrangement under Topic 718 or within the scope of other guidance. The ASU provides an illustrative example with multiple fact patterns and amends the structure of paragraph 718-10-15-3 of Topic 718 to improve its clarity and operability. The guidance in ASU 2024-01 applies to all entities that issue profits interest awards as compensation to employees or nonemployees in exchange for goods or services. Entities can apply the amendments either retrospectively to all periods presented in the financial statements or prospectively to profits interest awards granted or modified on or after the date of adoption. If prospective application is elected, an entity must disclose the nature of and reason for the change in accounting principle that resulted from the adoption of the ASU. This ASU is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. We do not expect that the requirements of ASU 2024 – 01 will have a material impact on our consolidated financial statements. In December 2023, FASB issued ASU 2023-09, “ Income Taxes (Topic 740): Improvements to Income Tax Disclosures ,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023-09 will have on our consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segments ,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the chief operating decision maker uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments, aggregates those operating segments or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating the impact that ASU 2023- 07 will have on our consolidated financial statements.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org//250/tableOfContent

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

+ Details

Comprehensive Income	6 Months Ended
Comprehensive Income	Jun. 29, 2024
Comprehensive Income [Abstract]
Comprehensive Income	Note 14 – Comprehensive Income Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income and are recorded directly to stockholders’ equity. The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of: June 29, December 30, 2024 2023 Attributable to redeemable noncontrolling interests: Foreign currency translation adjustment $ (47) $ (32) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (289) $ (188) Unrealized gain (loss) from hedging activities 2 (13) Pension adjustment loss (5) (5) Accumulated other comprehensive loss $ (292) $ (206) Total Accumulated other comprehensive loss $ (340) $ (239) The following table summarizes the components of comprehensive income, net of applicable taxes as follows: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Net income $ 105 $ 148 $ 203 $ 276 Foreign currency translation gain (loss) (62) 3 (116) 28 Tax effect - - - - Foreign currency translation gain (loss) (62) 3 (116) 28 Unrealized gain (loss) from hedging activities 6 (2) 21 (6) Tax effect (2) 1 (6) 2 Unrealized gain (loss) from hedging activities 4 (1) 15 (4) Comprehensive income $ 47 $ 150 $ 102 $ 300 Our financial statements are denominated in U.S. Dollars. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain (loss) during the six months ended June 29, 2024 and six months ended July 1, 2023 was primarily due to changes in foreign currency exchange rates of the Brazilian Real, Euro, British Pound, Canadian Dollar, Australian Dollar and Swiss Franc. The hedging gain (loss) during the three and six months ended June 29, 2024, and July 1, 2023 was attributable to a net investment hedge. The following table summarizes our total comprehensive income, net of applicable taxes as follows: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Comprehensive income attributable to Henry Schein, Inc. $ 51 $ 143 $ 111 $ 284 Comprehensive income attributable to noncontrolling interests 4 3 7 6 Comprehensive income (loss) attributable to Redeemable noncontrolling interests (8) 4 (16) 10 Comprehensive income $ 47 $ 150 $ 102 $ 300

Redeemable Noncontrolling Interests - Components of the Change in Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period			$ 864	$ 576	$ 576
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries			(205)		(19)
Increase in redeemable noncontrolling interests due to business acquisitions			154		326
Net income (loss) attributable to redeemable noncontrolling interests	$ (3)	$ 5	(1)	9	6
Distributions declared, net of capital contributions			(22)		(19)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(5)	$ (1)	(15)	$ 1	5
Change in fair value of redeemable securities			81		(11)
Balance, end of period	$ 856		$ 856		$ 864

- Definition

Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023
Net income (loss) attributable to redeemable noncontrolling interests	$ (3)	$ 5	$ (1)	$ 9	$ 6
Foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(5)	(1)	(15)	1	$ 5
Unrealized gain (loss) from foreign currency hedging activities, tax (benefit)	$ 2	$ (1)	$ 6	$ (2)

Debt - Schedule of Bank Credit Lines (Details) - USD ($) $ in Millions	Jun. 29, 2024	Dec. 30, 2023
Line of Credit Facility [Line Items]
Bank Credit lines	$ 505	$ 264
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	0	200
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	$ 505	$ 64

Net Sales from Contracts with Customers	6 Months Ended
Net Sales from Contracts with Customers	Jun. 29, 2024
Net Sales from Contracts with Customers [Abstract]
Net Sales from Contracts with Customers	Note 4 – Net Sales from Contracts with Customers Net sales are recognized in accordance with policies disclosed in Item 8 of our Annual Report on Form 10-K for the year ended December 30, 2023. Disaggregation of Net Sales The following table disaggregates our net sales by reportable and operating segment and geographic area: Three Months Ended Six Months Ended June 29, 2024 June 29, 2024 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,129 $ 795 $ 1,924 $ 2,232 $ 1,606 $ 3,838 Medical 970 28 998 1,984 55 2,039 Total health care distribution 2,099 823 2,922 4,216 1,661 5,877 Technology and value-added services 186 28 214 375 56 431 Total net sales $ 2,285 $ 851 $ 3,136 $ 4,591 $ 1,717 $ 6,308 Three Months Ended Six Months Ended July 1, 2023 July 1, 2023 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,169 $ 788 $ 1,957 $ 2,313 $ 1,542 $ 3,855 Medical 925 25 950 1,876 45 1,921 Total health care distribution 2,094 813 2,907 4,189 1,587 5,776 Technology and value-added services 168 25 193 334 50 384 Total net sales $ 2,262 $ 838 $ 3,100 $ 4,523 $ 1,637 $ 6,160 Contract Liabilities At June 29, 2024, December 30, 2023, and December 31, 2022, the current and non-current contract liabilities were $ 77 million and $ 8 million; $ 89 million and $ 9 million; and $ 86 million and $ 8 million, respectively. During the six months ended June 29, 2024, we recognized, in net sales, $ 55 million of the amount that was previously deferred at December 30, 2023. During the six months ended July 1, 2023, we recognized in net sales $ 56 million of the amount that was previously deferred at December 31, 2022. Current contract liabilities are included in accrued expenses: other and the non-current contract liabilities are included in other liabilities within our consolidated balance sheets.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

Plans of Restructuring - Schedule of Restructuring Reserve by Segment (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Restructuring Cost and Reserve [Line Items]
Balance, beginning			$ 23
Restructuring costs	$ 15	$ 18	25	$ 48
Non-cash accelerated depreciation and amortization			(6)
Cash payments and other adjustments			21
Balance, ending	21		21
Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning			22
Restructuring costs	14	16	23	42
Non-cash accelerated depreciation and amortization			(6)
Cash payments and other adjustments			18
Balance, ending	21		21
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning			1
Restructuring costs	1	$ 2	2	$ 6
Non-cash accelerated depreciation and amortization			0
Cash payments and other adjustments			3
Balance, ending	$ 0		$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Debt - Revolving Credit Agreement Narrative (Details) - Revolving Credit Agreement [Member] - USD ($) $ in Millions		6 Months Ended	12 Months Ended
	Aug. 20, 2021	Jun. 29, 2024	Dec. 30, 2023
Line of Credit Facility [Line Items]
Line of credit initiation date	Aug. 20, 2021	Jul. 11, 2023
Credit facility borrowing capacity		$ 1,000
Credit facility expiration date		Jul. 11, 2028
Line of credit interest rate		5.33%	5.36%
Debt instrument, basis spread on variable rate		1.10%	1.00%
Line of credit combined interest rate		6.43%	6.36%
Borrowings		$ 0	$ 200
Outstanding letters of credit provided to third parties		11	$ 10
Average amount outstanding		$ 77

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)			2 years 7 months 6 days
Grants in period (in shares)			0
Total unrecognized compensation cost related to non-vested awards	$ 104		$ 104
Expected life of options (years)			6 years
Pre-tax share-based compensation (Credit) expense	$ 12	$ 14	$ 20	$ 24
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years
Percentage of stock options vest per year			33.33%
Expiration period (in years)			10 years
Time-Based Restricted Stock/Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			4 years
Time-Based Restricted Stock/Restricted Units [Member] \| 2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			12 months
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years

Business Acquisitions	6 Months Ended
Business Acquisitions	Jun. 29, 2024
Business Acquisitions [Abstract]
Business Acquisitions	Note 6 – Business Acquisitions Our acquisition strategy is focused on investments in companies that add new customers and sales teams, increase our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we have already invested in businesses), and finally, those that enable us to access new products and technologies. Acquisition of TriMed On April 1, 2024, we acquired a 60 % voting equity interest in TriMed Inc. (“TriMed”), a global developer of solutions for the orthopedic treatment of lower and upper extremities, headquartered in California. The following table aggregates the preliminary estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired in the TriMed acquisition: 2024 Acquisition consideration: Cash $ 141 Deferred consideration 22 Redeemable noncontrolling interests 153 Total consideration $ 316 Identifiable assets acquired and liabilities assumed: Current assets $ 36 Intangible assets 221 Other noncurrent assets 10 Current liabilities (9) Deferred income taxes (62) Other noncurrent liabilities (6) Total identifiable net assets 190 Goodwill 126 Total net assets acquired $ 316 Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of TriMed. The acquired goodwill is not deductible for tax purposes. The following table summarizes the preliminary identifiable intangible assets acquired as part of the acquisition of TriMed: 2024 Weighted Average Useful Lives (in years) Product development $ 204 9 Trademarks / Tradenames 9 7 In process research & development 8 - Total $ 221 The accounting for the acquisition of TriMed has not been completed in several areas, including but not limited to pending assessments of accounts receivable, inventory, intangible assets, right-of-use lease assets, accrued liabilities, income and non-income based taxes and valuation of redeemable noncontrolling interests. To assist management in the allocation, we engaged valuation specialists to prepare appraisals. We will finalize the amounts recognized as the information necessary to complete the analysis is obtained. We expect to finalize these amounts as soon as possible but no later than one year from the acquisition date. The pro forma financial information has not been presented because the impact of the TriMed acquisition during the three and six months ended June 29, 2024 was immaterial to our condensed consolidated financial statements. Other 2024 Acquisitions During the six months ended June 29, 2024, we acquired companies within the health care distribution and technology and value-added services segments. Our acquired ownership interest in these companies range from 51 % to 100 %. Total consideration for these acquisitions was $ 23 million. Net assets acquired primarily consisted of $ 13 million of goodwill and $ 14 million of intangible assets. The intangible assets acquired consisted of customer relationships and lists of $ 7 million, product development of $ 4 million, non-compete agreements of $ 2 million and trademarks and tradenames of $ 1 million. Weighted average useful lives for these acquired intangible assets were 10 years, 10 years, 5 years and 5 years, respectively. Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions are expected to provide for us, as well as the expected growth potential. Approximately half of the acquired goodwill is deductible for tax purposes. The impact of these acquisitions, individually and in the aggregate, was not considered material to our condensed consolidated financial statements. 2023 Acquisitions Acquisition of Shield Healthcare On October 2, 2023 we acquired a 90 % voting equity interest in Shield Healthcare, Inc. (“Shield”), a supplier of homecare medical products delivered directly to patients in their homes, for consideration of $ 348 million (including cash paid of $ 289 million, deferred consideration of $ 22 million and redeemable noncontrolling interests of $ 37 million). Shield expands our existing medical business by delivering a diverse range of products, including items such as incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes supplies. Additionally, Shield offers continuous glucose monitoring devices directly to patients in their homes. During the quarter ended June 29, 2024, we completed the accounting for our acquisition of Shield. The following table aggregates the final fair value, as of the date of the acquisition, of consideration paid and net assets acquired in the Shield acquisition, including measurement period adjustments recorded through June 29, 2024: Preliminary Allocation as of December 30, 2023 Measurement Period Adjustments Final Allocation Acquisition consideration: Cash $ 286 $ 3 $ 289 Deferred consideration 43 (21) 22 Redeemable noncontrolling interests 37 - 37 Total consideration $ 366 $ (18) $ 348 Identifiable assets acquired and liabilities assumed: Current assets $ 41 $ - $ 41 Intangible assets 166 - 166 Other noncurrent assets 14 2 16 Current liabilities (24) - (24) Deferred income taxes (41) (2) (43) Other noncurrent liabilities (7) - (7) Total identifiable net assets 149 - 149 Goodwill 217 (18) 199 Total net assets acquired $ 366 $ (18) $ 348 Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of Shield. The acquired goodwill is not deductible for tax purposes. The following table summarizes the identifiable intangible assets acquired as part of the acquisition of Shield: 2023 Weighted Average Useful Lives (in years) Customer relationships and lists $ 156 12 Trademarks / Tradenames 10 5 Total $ 166 The pro forma financial information has not been presented because the impact of the Shield acquisition was immaterial to our consolidated financial statements. Acquisition of S.I.N. Implant System On July 5, 2023, we acquired a 100 % voting equity interest in S.I.N. Implant System (“S.I.N.”) for consideration of $ 329 million. Based in São Paulo, S.I.N. manufactures an extensive line of products to perform dental implant procedures and is focused on advancing the development of value-priced dental implants. In 2023, S.I.N. expanded the distribution of its products into the United States and other international markets During the quarter ended June 29, 2024, we completed the accounting for our acquisition of S.I.N. The following table aggregates the final fair value, as of the date of acquisition, of consideration paid and net assets acquired in the S.I.N. acquisition, including measurement period adjustments: Preliminary Allocation as of December 30, 2023 Measurement Period Adjustments Final Allocation Acquisition consideration: Cash $ 329 $ - $ 329 Total consideration $ 329 $ - $ 329 Identifiable assets acquired and liabilities assumed: Current assets $ 67 $ 6 $ 73 Intangible assets 87 - 87 Other noncurrent assets 46 2 48 Current liabilities (33) - (33) Long-term debt (22) - (22) Deferred income taxes (35) (3) (38) Other noncurrent liabilities (27) - (27) Total identifiable net assets 83 5 88 Goodwill 246 (5) 241 Total net assets acquired $ 329 $ - $ 329 Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of S.I.N. The acquired goodwill is not deductible for tax purposes. 2023 Weighted Average Useful Lives (in years) Customer relationships and lists $ 38 7 Product development 36 8 Trademarks / Tradenames 13 10 Total $ 87 The pro forma financial information has not been presented because the impact of the S.I.N. acquisition was immaterial to our consolidated financial statements. Acquisition of Biotech Dental On April 5, 2023, we acquired a 57 % voting equity interest, for preliminary consideration of $ 423 million (including cash paid of $ 216 million, $ 25 million of contributed equity share in a controlled subsidiary, and redeemable noncontrolling interests of $ 182 million) in Biotech Dental (“Biotech Dental”), which is a provider of dental implants, clear aligners, individualized prosthetics and innovative digital dental software based in France. Biotech Dental has several important solutions for dental practices and dental labs, including Nemotec, a comprehensive, integrated suite of planning and diagnostic software using open architecture that connects disparate medical devices to create a digital view of the patient, offering greater diagnostic accuracy and an improved patient experience. The integration of Biotech Dental’s software with Henry Schein One’s industry-leading practice management software solutions will help customers streamline their clinical as well as administrative workflow for the ultimate benefit of patients. During the quarter ended March 30, 2024, we completed the accounting for our acquisition of Biotech Dental. The following table aggregates the final fair value, as of the date of acquisition, of consideration paid and net assets acquired in the Biotech Dental acquisition, including measurement period adjustments: Final Allocation Acquisition consideration: Cash $ 216 Fair value of contributed equity share in a controlled subsidiary 25 Redeemable noncontrolling interests 182 Total consideration $ 423 Identifiable assets acquired and liabilities assumed: Current assets $ 74 Intangible assets 189 Other noncurrent assets 69 Current liabilities (60) Long-term debt (73) Deferred income taxes (53) Other noncurrent liabilities (20) Total identifiable net assets 126 Goodwill 297 Total net assets acquired $ 423 Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of Biotech Dental. The acquired goodwill is not deductible for tax purposes. The following table summarizes the identifiable intangible assets acquired as part of the acquisition of Biotech Dental: 2023 Weighted Average Useful Lives (in years) Product development $ 124 10 Customer relationships and lists 47 9 Trademarks / Tradenames 18 7 Total $ 189 The pro forma financial information has not been presented because the impact of the Biotech Dental acquisition was immaterial to our condensed consolidated financial statements. Other 2023 Acquisitions During the year ended December 30, 2023, in addition to those noted above, we acquired companies within the health care distribution and technology and value-added services segments. Our acquired ownership interest ranged between 51 % to 100 %. During the three and six months ended June 29, 2024, we recorded an adjustment of $ 23 million and $ 38 million, respectively, within the selling, general and administrative line in our condensed consolidated statements of income, representing a change in the fair value of contingent consideration related to a 2023 acquisition. During the six months ended June 29, 2024 we completed the accounting for certain acquisitions that occurred in the year ended December 30, 2023. In relation to these acquisitions, we did not record material adjustments in our condensed consolidated financial statements relating to changes in estimated values of assets acquired, liabilities assumed and contingent consideration assets and liabilities. Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions are expected to provide for us, as well as the expected growth potential. The majority of the acquired goodwill is deductible for tax purposes. The pro forma financial information for our 2023 acquisitions has not been presented because the impact of the acquisitions was immaterial to our condensed consolidated financial statements. Acquisition Costs During the three and six months ended June 29, 2024 we incurred $ 1 million and $ 3 million in acquisition costs, respectively. During the three and six months ended July 1, 2023 we incurred $ 6 million and $ 13 million in acquisition costs, respectively. These costs are included in the selling, general and administrative line in our condensed consolidated statements of income.

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 29, 2024	Jul. 29, 2024
Cover [Abstract]
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-28
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 29, 2024
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN, INC.
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		126,707,799

Business Acquisitions - Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives (Details) - USD ($) $ in Millions	Apr. 01, 2024	Oct. 02, 2023	Jul. 05, 2023	Apr. 05, 2023
TriMed, Inc. [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 221
TriMed, Inc. [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 204
Estimated useful lives (in years)	9 years
TriMed, Inc. [Member] \| Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 9
Estimated useful lives (in years)	7 years
TriMed, Inc. [Member] \| In Process Research And Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 8
Estimated useful lives (in years)	0 years
Shield Healthcare, Inc. [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 166
Shield Healthcare, Inc. [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 156
Estimated useful lives (in years)		12 years
Shield Healthcare, Inc. [Member] \| Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 10
Estimated useful lives (in years)		5 years
S.I.N. Implant System [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 87
S.I.N. Implant System [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 38
Estimated useful lives (in years)			7 years
S.I.N. Implant System [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 36
Estimated useful lives (in years)			8 years
S.I.N. Implant System [Member] \| Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 13
Estimated useful lives (in years)			10 years
Biotech Dental [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired				$ 189
Biotech Dental [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired				$ 124
Estimated useful lives (in years)				10 years
Biotech Dental [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired				$ 18
Estimated useful lives (in years)				7 years
Biotech Dental [Member] \| Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired				$ 47
Estimated useful lives (in years)				9 years

Debt - Term Loan Narrative (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 29, 2024	Dec. 30, 2023
Term Credit Agreement [Member]
Line of Credit Facility [Line Items]
Debt face amount	$ 750
Debt term (in years)	3 years
Long-term debt	$ 731	$ 741
Term Credit Agreement [Member] \| Interest Rate Swap [Member]
Line of Credit Facility [Line Items]
Derivative fixed interest rate	5.91%	5.79%
Term Credit Agreement [Member] \| Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member]
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage	5.33%	5.36%
Debt instrument, basis spread on variable rate	1.47%	1.35%
Debt instrument, interest rate at period end	6.80%	6.71%
September 2024 through June 2026 [Member]
Line of Credit Facility [Line Items]
Quarterly payments	$ 9
September 2023 through June 2024 [Member]
Line of Credit Facility [Line Items]
Quarterly payments	$ 5

Earnings Per Share - Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Weighted-average common shares outstanding:
Basic (in shares)	127,784,380	130,905,899	128,252,628	131,136,450
Effect of dilutive securities:
Stock options and restricted stock units	862,126	967,275	954,152	1,329,299
Diluted (in shares)	128,646,506	131,873,174	129,206,780	132,465,749

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]
Net income	$ 105	$ 148	$ 203	$ 276
Other comprehensive income, net of tax:
Foreign currency translation gain (loss)	(62)	3	(116)	28
Unrealized gain (loss) from foreign currency hedging activities	4	(1)	15	(4)
Other comprehensive income (loss), net of tax	(58)	2	(101)	24
Comprehensive income	47	150	102	300
Comprehensive income attributable to noncontrolling interests:
Net income	(1)	(8)	(6)	(15)
Foreign currency translation loss (gain)	5	1	15	(1)
Comprehensive (income) loss attributable to noncontrolling interests	4	(7)	9	(16)
Comprehensive income attributable to Henry Schein, Inc.	$ 51	$ 143	$ 111	$ 284

Stock-Based Compensation - Status of Unvested RSUs (Details)	6 Months Ended
	Jun. 29, 2024 $ / shares shares
Time-Based Restricted Stock/Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	1,655,393
Granted (in shares) \| shares	461,798
Vested (in shares) \| shares	(321,460)
Forfeited (in shares) \| shares	(59,283)
Ending balance outstanding (in shares) \| shares	1,736,448
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 70.34
Granted (in dollars per share)	75.88
Vested (in dollars per share)	62.79
Forfeited (in dollars per share)	77.31
Ending balance outstanding (in dollars per share)	72.99
Aggregate intrinsic value	$ 64.10
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	208,742
Granted (in shares) \| shares	408,681
Vested (in shares) \| shares	(8,262)
Forfeited (in shares) \| shares	(35,527)
Ending balance outstanding (in shares) \| shares	573,634
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 78.02
Granted (in dollars per share)	76.31
Vested (in dollars per share)	66.53
Forfeited (in dollars per share)	80.55
Ending balance outstanding (in dollars per share)	75.78
Aggregate intrinsic value	$ 64.10

Basis of Presentation (Policy)	6 Months Ended
Basis of Presentation (Policy)	Jun. 29, 2024
Basis of Presentation [Abstract]
Principles of Consolidation	Our condensed consolidated financial statements include the accounts of Henry Schein, Inc., and all of our controlled subsidiaries (“we”, “us” and “our”). All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates for which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications, individually and in the aggregate, did not have a material impact on our condensed consolidated financial condition, results of operations or cash flows.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the three and six months ended June 29, 2024 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 28, 2024.
Consolidated Variable Interest Entity	We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a VIE because we are its primary beneficiary, as we have the power to direct activities that most significantly affect its economic performance and have the obligation to absorb the majority of its losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The VIE’s creditors have recourse to us for losses on these trade accounts receivable. At June 29, 2024 and December 30, 2023, certain trade accounts receivable that can only be used to settle obligations of this VIE were $ 330 million and $ 284 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were $ 195 million and $ 210 million, respectively.

Legal Proceedings	6 Months Ended
Legal Proceedings	Jun. 29, 2024
Legal Proceedings [Abstract]
Legal Proceedings	Note 11 – Legal Proceedings Henry Schein, Inc. has been named as a defendant in multiple opioid related lawsuits (currently less than one- hundred and seventy-five ( 175 ); one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant in a number of those cases). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and its subsidiaries) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and others which remain pending in state courts and are proceeding independently and outside of the MDL. At this time, the following case is set for trial: the action filed by Florida Health Sciences Center, Inc. (and 25 other hospitals located throughout the State of Florida) in Florida state court, which is currently scheduled for a jury trial in September 2025. Of Henry Schein’s 2023 net sales of approximately $ 12.3 billion, sales of opioids represented less than four - tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions. In August 2022, Henry Schein received a Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia, seeking documents in connection with an investigation of possible violations of the Federal Food, Drug & Cosmetic Act by Butler Animal Health Supply, LLC (“Butler”), a former subsidiary of Henry Schein. The investigation relates to the sale of veterinary prescription drugs to certain customers. In October 2022, Henry Schein received a second Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia. The October 2022 Subpoena seeks documents relating to payments Henry Schein received from Butler or Covetrus, Inc. (“Covetrus”). Butler was spun off into a separate company and became a subsidiary of Covetrus in 2019 and is no longer owned by Henry Schein. We are cooperating with the investigation. On January 18, 2024, a putative class action was filed against the Company in the U.S. District Court for the Eastern District of New York (“EDNY”), Case No. 24-cv-387 (the “Cruz-Bermudez Action”), based on the October 2023 cyber incident described in On January 26, 2024, a second putative class action was filed against the Company based on the cyber incident, also in the EDNY, Case No. 24-cv-550 (the “Depperschmidt Action”). On February 12, 2024, the Depperschmidt Action was voluntarily dismissed without prejudice. On February 16, 2024, an amended complaint was filed in the Cruz-Bermudez Action with additional plaintiffs’ counsel from the Depperschmidt Action and an additional new plaintiff. Plaintiffs in the Cruz-Bermudez Action seek to represent a class of all individuals whose personally identifying information and personal health information was compromised by the incident. Plaintiffs generally claim to have been harmed by alleged actions and/or omissions by the Company in connection with the incident and that the Company made deceptive public statements regarding privacy and data protection. Plaintiffs assert a variety of claims seeking monetary damages, injunctive relief, costs and attorneys’ fees, and other related relief. On March 22, 2024, plaintiffs voluntarily withdrew two of their five causes of action. On April 8, 2024, the court denied the Company’s motion to dismiss the remaining claims. The case remains pending. On June 6, 2024, plaintiffs and the Company informed the court that they had agreed to a term sheet for a class action settlement of the Cruz-Bermudez Action. The settlement agreement is subject to the parties’ finalization and the court’s approval. The final settlement terms enumerated in a settlement agreement, including the settlement amount, will depend in part on the outcome of Henry Schein’s review of the data impacted in the cyber incident to determine the final class size total. The court stayed the Cruz-Bermudez Action through September 13, 2024 and ordered plaintiffs to move for preliminary approval of the proposed settlement by that date. We expect any settlement will be for an immaterial amount. Henry Schein, Inc. and its subsidiary, North American Rescue, LLC (“NAR”), have been named as defendants in a qui tam lawsuit brought under the federal False Claims Act (“FCA”), in an action entitled Russ and Murphy ex rel. United States v. North American Rescue, LLC et al. ; Case No. 21-cv-04238, filed in the United States District Court for the Eastern District of Pennsylvania. The case was filed under seal in 2021 by two relators (Corey Russ and Chris Murphy) who worked for one of NAR’s competitors. Relators also name C-A-T Resources, LLC (“CAT-R”) as a defendant. CAT -R manufactures one of the products at issue in the case (the combat application tourniquet, or “CAT”). After the Department of Justice declined to intervene, the case was unsealed, and Relators filed their first amended complaint in November 2023. In response to motions to dismiss filed by Henry Schein, NAR and CAT- R, Relators requested and obtained leave to file their Second Amended Complaint on April 24, 2024. Relators’ FCA claims are based on allegations that NAR and Henry Schein made false representations and certifications in connection with, and sold and submitted false claims for payment to the federal government for, various medical products that Relators contend violated certain “Buy American” laws (e.g., the Berry Amendment and Trade Agreements Act of 1979) and/or were not properly sterilized as noted on the products’ packaging, and thus misbranded. These products include the CAT, syringes, compressed gauze, tracheostomy kits, hypothermia blankets, eye, ear, nose and throat kits, and trauma dressing. Relators allege Henry Schein controlled and supervised NAR’s alleged misconduct for a period of time. Relators seek three times the amount of damages to be proved at trial, statutory civil penalties, reasonable expenses, attorneys’ fees and costs, and prejudgment interest. On July 26, 2024, the court ruled on motions to dismiss filed by Henry Schein, NAR and CAT-R. The court dismissed the claims against Henry Schein (without prejudice) and Henry Schein is no longer in the case. The motions to dismiss filed by NAR and CAT-R were denied. We intend to defend ourselves vigorously against this action. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of June 29, 2024, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Business Acquisitions (Tables)	6 Months Ended
Business Acquisitions (Tables)	Jun. 29, 2024
TriMed, Inc. [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	2024 Acquisition consideration: Cash $ 141 Deferred consideration 22 Redeemable noncontrolling interests 153 Total consideration $ 316 Identifiable assets acquired and liabilities assumed: Current assets $ 36 Intangible assets 221 Other noncurrent assets 10 Current liabilities (9) Deferred income taxes (62) Other noncurrent liabilities (6) Total identifiable net assets 190 Goodwill 126 Total net assets acquired $ 316
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2024 Weighted Average Useful Lives (in years) Product development $ 204 9 Trademarks / Tradenames 9 7 In process research & development 8 - Total $ 221
Shield Healthcare, Inc. [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	Preliminary Allocation as of December 30, 2023 Measurement Period Adjustments Final Allocation Acquisition consideration: Cash $ 286 $ 3 $ 289 Deferred consideration 43 (21) 22 Redeemable noncontrolling interests 37 - 37 Total consideration $ 366 $ (18) $ 348 Identifiable assets acquired and liabilities assumed: Current assets $ 41 $ - $ 41 Intangible assets 166 - 166 Other noncurrent assets 14 2 16 Current liabilities (24) - (24) Deferred income taxes (41) (2) (43) Other noncurrent liabilities (7) - (7) Total identifiable net assets 149 - 149 Goodwill 217 (18) 199 Total net assets acquired $ 366 $ (18) $ 348
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Weighted Average Useful Lives (in years) Customer relationships and lists $ 156 12 Trademarks / Tradenames 10 5 Total $ 166
S.I.N [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	Preliminary Allocation as of December 30, 2023 Measurement Period Adjustments Final Allocation Acquisition consideration: Cash $ 329 $ - $ 329 Total consideration $ 329 $ - $ 329 Identifiable assets acquired and liabilities assumed: Current assets $ 67 $ 6 $ 73 Intangible assets 87 - 87 Other noncurrent assets 46 2 48 Current liabilities (33) - (33) Long-term debt (22) - (22) Deferred income taxes (35) (3) (38) Other noncurrent liabilities (27) - (27) Total identifiable net assets 83 5 88 Goodwill 246 (5) 241 Total net assets acquired $ 329 $ - $ 329
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Weighted Average Useful Lives (in years) Customer relationships and lists $ 38 7 Product development 36 8 Trademarks / Tradenames 13 10 Total $ 87
Biotech Dental [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	Final Allocation Acquisition consideration: Cash $ 216 Fair value of contributed equity share in a controlled subsidiary 25 Redeemable noncontrolling interests 182 Total consideration $ 423 Identifiable assets acquired and liabilities assumed: Current assets $ 74 Intangible assets 189 Other noncurrent assets 69 Current liabilities (60) Long-term debt (73) Deferred income taxes (53) Other noncurrent liabilities (20) Total identifiable net assets 126 Goodwill 297 Total net assets acquired $ 423
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Weighted Average Useful Lives (in years) Product development $ 124 10 Customer relationships and lists 47 9 Trademarks / Tradenames 18 7 Total $ 189

Comprehensive Income - Total Comprehensive Income, Net of Applicable Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income attributable to Henry Schein, Inc.	$ 51	$ 143	$ 111	$ 284
Comprehensive income attributable to noncontrolling interests	4	3	7	6
Comprehensive income (loss) attributable to Redeemable noncontrolling interests	(8)	4	(16)	10
Comprehensive income	$ 47	$ 150	$ 102	$ 300

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

Significant Accounting Policies and Recently Issued Accounting Standards (Policy)	6 Months Ended
	Jun. 29, 2024
Significant Accounting Policies and Recently Issued Accounting Standards [Abstract]
Recently Issued Accounting Standards	Recently Issued Accounting Standards In March 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-01, “ Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards, ” which clarifies how to determine whether a profit interest and similar awards should be accounted for as a share-based payment arrangement under Topic 718 or within the scope of other guidance. The ASU provides an illustrative example with multiple fact patterns and amends the structure of paragraph 718-10-15-3 of Topic 718 to improve its clarity and operability. The guidance in ASU 2024-01 applies to all entities that issue profits interest awards as compensation to employees or nonemployees in exchange for goods or services. Entities can apply the amendments either retrospectively to all periods presented in the financial statements or prospectively to profits interest awards granted or modified on or after the date of adoption. If prospective application is elected, an entity must disclose the nature of and reason for the change in accounting principle that resulted from the adoption of the ASU. This ASU is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. We do not expect that the requirements of ASU 2024 – 01 will have a material impact on our consolidated financial statements. In December 2023, FASB issued ASU 2023-09, “ Income Taxes (Topic 740): Improvements to Income Tax Disclosures ,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023-09 will have on our consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280): Improvements to Reportable Segments ,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the chief operating decision maker uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments, aggregates those operating segments or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating the impact that ASU 2023- 07 will have on our consolidated financial statements.

Earnings Per Share (Tables)	6 Months Ended
Earnings Per Share (Tables)	Jun. 29, 2024
Earnings Per Share [Abstract]
Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted	Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Basic 127,784,380 130,905,899 128,252,628 131,136,450 Effect of dilutive securities: Stock options and restricted stock units 862,126 967,275 954,152 1,329,299 Diluted 128,646,506 131,873,174 129,206,780 132,465,749
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Stock options 416,790 426,002 417,819 427,355 Restricted stock units 792,247 19,405 495,077 19,405 Total anti-dilutive securities excluded from earnings per share computation 1,209,037 445,407 912,896 446,760

Basis of Presentation - Narrative (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Millions	Jun. 29, 2024	Dec. 30, 2023
Asset Pledged as Collateral [Member]
Pledged assets	$ 330	$ 284
Recourse [Member]
Liabilities of VIE	$ 195	$ 210

Debt (Tables)	6 Months Ended
Debt (Tables)	Jun. 29, 2024
Debt [Abstract]
Schedule of Bank Credit Lines	June 29, December 30, 2024 2023 Revolving credit agreement $ - $ 200 Other short-term bank credit lines 505 64 Total $ 505 $ 264
Schedule of Long-Term Debt	June 29, December 30, 2024 2023 Private placement facilities $ 1,024 $ 1,074 Term loan 731 741 U.S. trade accounts receivable securitization 195 210 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2030 at interest rates from 0.00 % to 9.42 % at June 29, 2024 and from 0.00 % to 9.42 % at December 30, 2023 40 54 Finance lease obligations 7 8 Total 1,997 2,087 Less current maturities (106) (150) Total long-term debt $ 1,891 $ 1,937
Schedule of Private Placement Facility Borrowings	Amount of Date of Borrowing Borrowing Borrowing Outstanding Rate Due Date December 24, 2012 $ 50 3.00 % December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 May 4, 2023 75 4.79 May 4, 2028 May 4, 2023 75 4.84 May 4, 2030 May 4, 2023 75 4.96 May 4, 2033 May 4, 2023 150 4.94 May 4, 2033 Less: Deferred debt issuance costs (1) Total $ 1,024

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7

+ Details

Earnings Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	1,209,037	445,407	912,896	446,760
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	416,790	426,002	417,819	427,355
Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	792,247	19,405	495,077	19,405

Debt	6 Months Ended
Debt	Jun. 29, 2024
Debt [Abstract]
Debt	Note 8 – Debt Bank Credit Lines Bank credit lines consisted of the following: June 29, December 30, 2024 2023 Revolving credit agreement $ - $ 200 Other short-term bank credit lines 505 64 Total $ 505 $ 264 Revolving Credit Agreement On August 20, 2021 , we entered into a $ 1.0 billion revolving credit agreement (the “Revolving Credit Agreement”) which was subsequently amended and restated on July 11, 2023 to extend the maturity date to July 11, 2028 and update the interest rate provisions to reflect the current market approach for a multicurrency facility. The interest rate on this revolving credit facility is based on Term Secured Overnight Financing Rate (“Term SOFR”) plus a spread based on our leverage ratio at the end of each financial reporting quarter. As of June 29, 2024 the interest rate on this revolving credit agreement was 5.33 % plus 1.10 % for a combined rate of 6.43 %. As of December 30, 2023 the interest rate on this revolving credit agreement was 5.36 % plus 1.00 % for a combined rate of 6.36 %. The Revolving Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Revolving Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of June 29, 2024 and December 30, 2023, we had $ 0 million and $ 200 million in borrowings, respectively under this revolving credit facility. During the six months ended June 29, 2024, the average outstanding balance under the Revolving Credit Agreement was approximately $ 77 million. As of June 29, 2024 and December 30, 2023, there were $ 11 million and $ 10 million of letters of credit, respectively, provided to third parties under this Revolving Credit Agreement. Other Short-Term Bank Credit Lines As of June 29, 2024 and December 30, 2023, we had various other short-term bank credit lines available, in various currencies, with a maximum borrowing capacity of $ 586 million and $ 368 million, respectively. As of June 29, 2024 and December 30, 2023, $ 505 million and $ 64 million, respectively, were outstanding. During the six months ended June 29, 2024, the average outstanding balances under our various other short-term bank credit lines was approximately $ 263 million. At June 29, 2024 and December 30, 2023, borrowings under other short-term bank credit lines had weighted average interest rates of 6.15 % and 6.02 %, respectively. Long-term debt Long-term debt consisted of the following: June 29, December 30, 2024 2023 Private placement facilities $ 1,024 $ 1,074 Term loan 731 741 U.S. trade accounts receivable securitization 195 210 Various collateralized and uncollateralized loans payable with interest, in varying installments through 2030 at interest rates from 0.00 % to 9.42 % at June 29, 2024 and from 0.00 % to 9.42 % at December 30, 2023 40 54 Finance lease obligations 7 8 Total 1,997 2,087 Less current maturities (106) (150) Total long-term debt $ 1,891 $ 1,937 Private Placement Facilities Our private placement facilities include four insurance companies, have a total facility amount of $ 1.5 billion, and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through October 20, 2026 . The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness, and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates. The components of our private placement facility borrowings, which have a weighted average interest rate of 3.66 %, as of June 29, 2024 are presented in the following table: Amount of Date of Borrowing Borrowing Borrowing Outstanding Rate Due Date December 24, 2012 $ 50 3.00 % December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 May 4, 2023 75 4.79 May 4, 2028 May 4, 2023 75 4.84 May 4, 2030 May 4, 2023 75 4.96 May 4, 2033 May 4, 2023 150 4.94 May 4, 2033 Less: Deferred debt issuance costs (1) Total $ 1,024 Term Loan On July 11, 2023, we entered into a three-year $ 750 million term loan credit agreement (the “Term Credit Agreement”). The interest rate on this term loan is based on the Term SOFR plus a spread based on our leverage ratio at the end of each financial reporting quarter. This term loan matures on July 11, 2026. We have been required to make quarterly payments of $ 5 million from September 2023 through June 2024 and are required to make quarterly payments of $ 9 million from September 2024 through June 2026, with the remaining balance due in July 2026. As of June 29, 2024, the borrowings outstanding under this term loan were $ 731 million. At June 29, 2024, the interest rate under the Term Credit Agreement was 5.33 % plus 1.47 % for a combined rate of 6.80 %. As of December 30, 2023, the borrowings outstanding under this term loan were $ 741 million. At December 30, 2023, the interest rate under the Term Credit Agreement was 5.36 % plus 1.35 % for a combined rate of 6.71 %. However, we have a hedge in place that ultimately creates an effective fixed rate of 5.91 % and 5.79 % at June 29, 2024 and December 30, 2023, respectively. The Term Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Term Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. U.S. Trade Accounts Receivable Securitization We have a facility agreement based on our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years . This facility agreement has a purchase limit of $ 450 million with two banks as agents, and expires on December 15, 2025 . As of June 29, 2024 and December 30, 2023, the borrowings outstanding under this securitization facility were $ 195 million and $ 210 million, respectively. At June 29, 2024, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 5.49 % plus 0.75 %, for a combined rate of 6.24 %. At December 30, 2023, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 5.67 % plus 0.75 %, for a combined rate of 6.42 %. If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced. We are required to pay a commitment fee of 30 to 35 basis points depending upon program utilization.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Millions

Jun. 29, 2024

Dec. 30, 2023

Debt Instrument [Line Items]

Finance lease obligations

$ 7

$ 8

Total

1,997

2,087

Less current maturities

(106)

(150)

Long-term debt

^[1]

1,891

1,937

Term Credit Agreement [Member]

Debt Instrument [Line Items]

Long-term debt

731

741

Private Placement Facilities [Member]

Debt Instrument [Line Items]

Long-term debt

1,024

1,074

U.S. Trade Accounts Receivable Securitization [Member]

Debt Instrument [Line Items]

Long-term debt

195

210

Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2030 at Interest Rates from 0.00% to 9.42% at June 29, 2024 and from 0.00% to 9.42% at December 30, 2023 [Member]

Debt Instrument [Line Items]

Long-term debt

$ 40

$ 54

Debt Instrument [Line Items]

Borrowing Rate

0.00%

Debt Instrument [Line Items]

Borrowing Rate

9.42%

[1]	Amounts presented include balances held by our consolidated variable interest entity (“VIE”). At June 29, 2024 and December 30, 2023, includes trade accounts receivable of $ 330 million and $ 284 million, respectively, and long-term debt of $ 195 million and $ 210 million, respectively.

Earnings Per Share	6 Months Ended
Earnings Per Share	Jun. 29, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Note 15 – Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted- average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for unvested RSUs and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect. A reconciliation of shares used in calculating earnings per basic and diluted share follows: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Basic 127,784,380 130,905,899 128,252,628 131,136,450 Effect of dilutive securities: Stock options and restricted stock units 862,126 967,275 954,152 1,329,299 Diluted 128,646,506 131,873,174 129,206,780 132,465,749 The number of antidilutive securities that were excluded from the calculation of diluted weighted average common shares outstanding are as follows: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Stock options 416,790 426,002 417,819 427,355 Restricted stock units 792,247 19,405 495,077 19,405 Total anti-dilutive securities excluded from earnings per share computation 1,209,037 445,407 912,896 446,760

Business Acquisitions - Narrative (Details) - USD ($) $ in Millions					3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended
	Apr. 01, 2024	Oct. 02, 2023	Jul. 05, 2023	Apr. 05, 2023	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Mar. 30, 2024	Dec. 30, 2023
Business Acquisition [Line Items]
Goodwill					$ 3,905		$ 3,905			$ 3,875
Acquisition costs incurred					1	$ 6	3	$ 13
TriMed, Inc. [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired	60.00%
Total consideration	$ 316
Consideration paid	141
Deferred consideration	22
Redeemable noncontrolling interests	153
Goodwill	126
Intangible assets	$ 221
TriMed, Inc. [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	9 years
TriMed, Inc. [Member] \| Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	7 years
TriMed, Inc. [Member] \| In Process Research And Development [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)	0 years
Shield Healthcare, Inc. [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired		90.00%
Total consideration		$ 348					348			366
Consideration paid		289					289			286
Deferred consideration		22					22			43
Redeemable noncontrolling interests		$ 37					37			37
Goodwill					199		199			217
Intangible assets					166		166			166
Shield Healthcare, Inc. [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)		12 years
Shield Healthcare, Inc. [Member] \| Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)		5 years
S.I.N. Implant System [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired			100.00%
Total consideration			$ 329				329			329
Consideration paid							329			329
Goodwill					241		241			246
Intangible assets					87		87			$ 87
S.I.N. Implant System [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)			7 years
S.I.N. Implant System [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)			8 years
S.I.N. Implant System [Member] \| Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)			10 years
Biotech Dental [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired				57.00%
Total consideration				$ 423					$ 423
Consideration paid				216					216
Fair value of contributed equity share in a controlled subsidiary				25					25
Redeemable noncontrolling interests				$ 182					182
Goodwill									297
Intangible assets									$ 189
Biotech Dental [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)				10 years
Biotech Dental [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)				7 years
Biotech Dental [Member] \| Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)				9 years
Series Of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Total consideration							23
Goodwill					13		13
Intangible assets					14		14
Series Of Individually Immaterial Business Acquisitions [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Intangible assets					7		$ 7
Estimated useful lives (in years)							10 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Intangible assets					4		$ 4
Estimated useful lives (in years)							10 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Noncompete Agreements [Member]
Business Acquisition [Line Items]
Intangible assets					2		$ 2
Estimated useful lives (in years)							5 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Trademarks And Trade Names [Member]
Business Acquisition [Line Items]
Intangible assets					$ 1		$ 1
Estimated useful lives (in years)							5 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired					51.00%		51.00%			51.00%
Series Of Individually Immaterial Business Acquisitions [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired					100.00%		100.00%			100.00%
Other 2023 Acquisitions [Member]
Business Acquisition [Line Items]
Change in fair value of contingent consideration					$ 23		$ 38

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023
Related Party Transaction [Line Items]
Current operating lease liabilities	$ 75.0		$ 75.0		$ 80.0
Noncurrent operating lease liabilities	261.0		261.0		310.0
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Other liabilities	5.0		5.0		5.0
Due from related party	31.0		31.0		32.0
Revenues	12.0	$ 11.0	24.0	$ 23.0
Purchases from related party	2.0	3.0	5.0	5.0
Internet Brands Inc [Member]
Related Party Transaction [Line Items]
Other liabilities	11.0		$ 11.0		$ 1.0
Internet Brands Inc [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Period covered by agreement			10 years
Related party agreement amount			$ 31.0
Operating costs and expenses	8.0	$ 8.0	16.0	$ 16.0
Employees and Minority Shareholders [Member]
Related Party Transaction [Line Items]
Current operating lease liabilities	6.0		6.0
Noncurrent operating lease liabilities	$ 22.0		$ 22.0
Employees and Minority Shareholders [Member] \| Operating Lease Liabilities, Current [Member] \| Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage			7.50%		6.30%
Employees and Minority Shareholders [Member] \| Operating Lease Liabilities, Non-Current [Member] \| Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage			8.60%		7.40%
Employees and Minority Shareholders [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	2 months		2 months
Employees and Minority Shareholders [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	13 years		13 years

Supplemental Cash Flow Information	6 Months Ended
Supplemental Cash Flow Information	Jun. 29, 2024
Supplemental Cash Flow information [Abstract]
Supplemental Cash Flow Information	Note 16 – Supplemental Cash Flow Information Cash paid for interest and income taxes was: Six Months Ended June 29, July 1, 2024 2023 Interest $ 63 $ 32 Income taxes 82 118 For the six months ended June 29, 2024 and July 1, 2023, we had $ 21 million and $ (6) million of non-cash net unrealized gains (losses) related to hedging activities, respectively.

Debt - Schedule of Private Placement Facility Borrowings (Details) - Private Placement Facilities [Member] - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Less: Deferred debt issuance costs	$ (1)
Total	$ 1,024	$ 1,074
Debt Instrument, Maturity Date	Oct. 20, 2026
Private Placement Facilities 1 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Dec. 24, 2012
Long-term Debt, Gross	$ 50
Borrowing Rate	3.00%
Debt Instrument, Maturity Date	Dec. 24, 2024
Private Placement Facilities 2 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 16, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.42%
Debt Instrument, Maturity Date	Jun. 16, 2027
Private Placement Facilities 3 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 15, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.52%
Debt Instrument, Maturity Date	Sep. 15, 2029
Private Placement Facilities 4 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jan. 02, 2018
Long-term Debt, Gross	$ 100
Borrowing Rate	3.32%
Debt Instrument, Maturity Date	Jan. 02, 2028
Private Placement facilities 5 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 02, 2020
Long-term Debt, Gross	$ 100
Borrowing Rate	2.35%
Debt Instrument, Maturity Date	Sep. 02, 2030
Private Placement Facilities 6 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.48%
Debt Instrument, Maturity Date	Jun. 02, 2031
Private Placement Facilities 7 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.58%
Debt Instrument, Maturity Date	Jun. 02, 2033
Private Placement Facilities 8 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.79%
Debt Instrument, Maturity Date	May 04, 2028
Private Placement Facilities 9 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.84%
Debt Instrument, Maturity Date	May 04, 2030
Private Placement Facilities 10 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.96%
Debt Instrument, Maturity Date	May 04, 2033
Private Placement Facilities 11 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 150
Borrowing Rate	4.94%
Debt Instrument, Maturity Date	May 04, 2033

Supplemental Cash Flow Information (Tables)	6 Months Ended
Supplemental Cash Flow Information (Tables)	Jun. 29, 2024
Supplemental Cash Flow information [Abstract]
Cash paid for interest and income taxes	Six Months Ended June 29, July 1, 2024 2023 Interest $ 63 $ 32 Income taxes 82 118

Segment Data	6 Months Ended
Segment Data	Jun. 29, 2024
Segment Data [Abstract]
Segment Data	Note 5 – Segment Data We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base. Our global dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as group practices, and integrated delivery networks, among other providers across a wide range of specialties. Our dental and medical groups serve practitioners in 33 countries worldwide. The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment (“PPE”) products, vitamins and orthopedic implants. Our global technology and value-added services reportable segment provides software, technology and other value- added services to health care practitioners. Our technology offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services. The following tables present information about our reportable and operating segments: Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Net sales: Health care distribution (1) Dental $ 1,924 $ 1,957 $ 3,838 $ 3,855 Medical 998 950 2,039 1,921 Total health care distribution 2,922 2,907 5,877 5,776 Technology and value-added services (2) 214 193 431 384 Total $ 3,136 $ 3,100 $ 6,308 $ 6,160 Consists of consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE products, vitamins and orthopedic implants. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services. Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Operating Income: Health care distribution $ 146 $ 166 $ 272 $ 311 Technology and value-added services 13 35 37 65 Total $ 159 $ 201 $ 309 $ 376

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

Comprehensive Income (Tables)	6 Months Ended
Comprehensive Income (Tables)	Jun. 29, 2024
Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss Net of Applicable Taxes	June 29, December 30, 2024 2023 Attributable to redeemable noncontrolling interests: Foreign currency translation adjustment $ (47) $ (32) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (289) $ (188) Unrealized gain (loss) from hedging activities 2 (13) Pension adjustment loss (5) (5) Accumulated other comprehensive loss $ (292) $ (206) Total Accumulated other comprehensive loss $ (340) $ (239)
Components of Comprehensive Income, Net of Applicable Taxes	Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Net income $ 105 $ 148 $ 203 $ 276 Foreign currency translation gain (loss) (62) 3 (116) 28 Tax effect - - - - Foreign currency translation gain (loss) (62) 3 (116) 28 Unrealized gain (loss) from hedging activities 6 (2) 21 (6) Tax effect (2) 1 (6) 2 Unrealized gain (loss) from hedging activities 4 (1) 15 (4) Comprehensive income $ 47 $ 150 $ 102 $ 300
Total Comprehensive Income, Net of Applicable Taxes	Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Comprehensive income attributable to Henry Schein, Inc. $ 51 $ 143 $ 111 $ 284 Comprehensive income attributable to noncontrolling interests 4 3 7 6 Comprehensive income (loss) attributable to Redeemable noncontrolling interests (8) 4 (16) 10 Comprehensive income $ 47 $ 150 $ 102 $ 300

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Supplemental Cash Flow Information [Abstract]
Interest			$ 63	$ 32
Income taxes			82	118
Non-cash net unrealized gains related to foreign currency hedging activities	$ 6	$ (2)	$ 21	$ (6)

Redeemable Noncontrolling Interests (Tables)	6 Months Ended
Redeemable Noncontrolling Interests (Tables)	Jun. 29, 2024
Redeemable Noncontrolling Interests [Abstract]
Components of the Change in Redeemable Noncontrolling Interests	June 29, December 30, 2024 2023 Balance, beginning of period $ 864 $ 576 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (205) (19) Increase in redeemable noncontrolling interests due to business acquisitions 154 326 Net income (loss) attributable to redeemable noncontrolling interests (1) 6 Distributions declared, net of capital contributions (22) (19) Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests (15) 5 Change in fair value of redeemable securities 81 (11) Balance, end of period $ 856 $ 864

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	Jun. 29, 2024	Dec. 30, 2023
Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt (including bank credit lines)	$ 2,502	$ 2,351
Term Credit Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt face amount	$ 750

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Jun. 29, 2024	Dec. 30, 2023
Current assets:
Accounts receivable, allowances for credit losses (in dollars)	$ 82	$ 83
Inventory, reserves	$ 145	$ 192
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	127,080,545	129,247,765
Variable Interest Entity, Primary Beneficiary [Member] \| Recourse [Member]
Stockholders' equity:
Liabilities of VIE	$ 195	$ 210
Asset Pledged as Collateral [Member] \| Variable Interest Entity, Primary Beneficiary [Member]
Stockholders' equity:
Pledged assets	$ 330	$ 284

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Stock $.01 Par Value [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 31, 2022	$ 4,095	$ 1	$ 0	$ 3,678	$ (233)	$ 649
Beginning Balance, shares (in shares) at Dec. 31, 2022		131,792,817
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	267			261		6
Foreign currency translation gain (loss) (excluding loss amounts attributable to Redeemable noncontrolling interests)	27				27
Unrealized gain (loss) from hedging activities, net of tax	(4)				(4)
Distributions to noncontrolling shareholders	(27)					(27)
Change in fair value of redeemable securities	(14)		(14)
Noncontrolling interests and adjustments related to business acquisitions	(1)		1			(2)
Repurchases and retirement of common stock - Value	(151)		(20)	(131)
Repurchases and retirement of common stock - Shares		(1,862,014)
Stock-based compensation expense - Value	24		24
Stock-based compensation expense - Shares		1,036,898
Stock issued upon exercise of stock options - Value	1		1
Stock issued upon exercise of stock options - Shares		15,860
Shares withheld for payroll taxes - Value	(32)		(32)
Shares withheld for payroll taxes - Shares		(405,865)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		(890)
Transfer of charges in excess of capital	0		39	(39)
Ending Balance at Jul. 01, 2023	4,186	$ 1	0	3,769	(210)	626
Ending Balance, shares (in shares) at Jul. 01, 2023		130,576,806
Beginning Balance at Apr. 01, 2023	4,127	$ 1	0	3,684	(213)	655
Beginning Balance, shares (in shares) at Apr. 01, 2023		131,196,783
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	143			140		3
Foreign currency translation gain (loss) (excluding loss amounts attributable to Redeemable noncontrolling interests)	4				4
Unrealized gain (loss) from hedging activities, net of tax	(1)				(1)
Distributions to noncontrolling shareholders	(27)					(27)
Change in fair value of redeemable securities	(17)		(17)
Noncontrolling interests and adjustments related to business acquisitions	(4)		1			(5)
Repurchases and retirement of common stock - Value	(51)		(7)	(44)
Repurchases and retirement of common stock - Shares		(638,095)
Stock-based compensation expense - Value	14		14
Stock-based compensation expense - Shares		20,598
Stock issued upon exercise of stock options - Shares		5,081
Shares withheld for payroll taxes - Value	(3)		(3)
Shares withheld for payroll taxes - Shares		(6,671)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		(890)
Transfer of charges in excess of capital	0		11	(11)
Ending Balance at Jul. 01, 2023	4,186	$ 1	0	3,769	(210)	626
Ending Balance, shares (in shares) at Jul. 01, 2023		130,576,806
Beginning Balance at Dec. 30, 2023	$ 4,289	$ 1	0	3,860	(206)	634
Beginning Balance, shares (in shares) at Dec. 30, 2023	129,247,765	129,247,765
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	$ 204			197		7
Foreign currency translation gain (loss) (excluding loss amounts attributable to Redeemable noncontrolling interests)	(101)				(101)
Unrealized gain (loss) from hedging activities, net of tax	15				15
Distributions to noncontrolling shareholders	(5)					(5)
Change in fair value of redeemable securities	(81)		(81)
Noncontrolling interests and adjustments related to business acquisitions	(10)		(10)
Repurchases and retirement of common stock - Value	(176)		(24)	(152)
Repurchases and retirement of common stock - Shares		(2,414,434)
Stock-based compensation expense - Value	20		20
Stock-based compensation expense - Shares		330,098
Stock issued upon exercise of stock options - Value	$ 2		2
Stock issued upon exercise of stock options - Shares	44,750	25,240
Shares withheld for payroll taxes - Value	$ (9)		(9)
Shares withheld for payroll taxes - Shares		(108,163)
Settlement of stock-based compensation awards - Value	0		0
Settlement of stock-based compensation awards - Shares		39
Transfer of charges in excess of capital			102	(102)
Ending Balance at Jun. 29, 2024	$ 4,148	$ 1	0	3,803	(292)	636
Ending Balance, shares (in shares) at Jun. 29, 2024	127,080,545	127,080,545
Beginning Balance at Mar. 30, 2024	$ 4,237	$ 1	0	3,838	(239)	637
Beginning Balance, shares (in shares) at Mar. 30, 2024		128,480,909
Net income (excluding amounts attributable to Redeemable noncontrolling interests)	108			104		4
Foreign currency translation gain (loss) (excluding loss amounts attributable to Redeemable noncontrolling interests)	(57)				(57)
Unrealized gain (loss) from hedging activities, net of tax	4				4
Distributions to noncontrolling shareholders	(5)					(5)
Change in fair value of redeemable securities	(39)		(39)
Noncontrolling interests and adjustments related to business acquisitions	(11)		(11)
Repurchases and retirement of common stock - Value	(101)		(14)	(87)
Repurchases and retirement of common stock - Shares		(1,415,706)
Stock-based compensation expense - Value	12		12
Stock-based compensation expense - Shares		15,339
Stock issued upon exercise of stock options - Value	1		1
Stock issued upon exercise of stock options - Shares		4,301
Shares withheld for payroll taxes - Value	(1)		(1)
Shares withheld for payroll taxes - Shares		(4,298)
Transfer of charges in excess of capital	0		52	(52)
Ending Balance at Jun. 29, 2024	$ 4,148	$ 1	$ 0	$ 3,803	$ (292)	$ 636
Ending Balance, shares (in shares) at Jun. 29, 2024	127,080,545	127,080,545

Cyber Incident	6 Months Ended
Cyber Incident	Jun. 29, 2024
Cyber Incident [Abstract]
Cyber Incident	Note 3 – Cyber Incident In October 2023 Henry Schein experienced a cyber incident that primarily affected the operations of our North American and European dental and medical distribution businesses. Henry Schein One, our practice management software, revenue cycle management and patient relationship management solutions business, was not affected, and our manufacturing businesses were mostly unaffected. On November 22, 2023, we experienced a disruption of our ecommerce platform and related applications, which was remediated. During the three and six months ended June 29, 2024, we continued to experience a residual impact of the cyber events noted above relating primarily to decreased sales to episodic customers (customers that had generally registered a less continuous level of demand pre-incident). During the three and six months ended June 29, 2024, we incurred $ 3 million and $ 8 million, respectively, of expenses directly related to the cyber incident, mostly consisting of professional fees. We maintain cyber insurance, subject to certain retentions and policy limitations. With respect to the October 2023 cyber incident, we have a $ 60 million insurance policy, following a $ 5 million retention. During the three and six months ended June 29, 2024, we received insurance proceeds of $ 10 million, representing a partial insurance recovery of losses related to the cyber incident. The expenses and insurance recoveries related to the cyber incident are included in the selling, general and administrative line in our condensed consolidated statements of income.

Related Party Transactions	6 Months Ended
Related Party Transactions	Jun. 29, 2024
Related Party Transactions [Abstract]
Related Party Transactions	Note 17 – Related Party Transactions In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $ 31 million annually for the use of their intellectual property. During the three and six months ended June 29, 2024, we recorded $ 8 million and $ 16 million, respectively, in connection with costs related to this royalty agreement. During the three and six months ended July 1, 2023, we recorded $ 8 million and $ 16 million, respectively, in connection with costs related to this royalty agreement. As of June 29, 2024 and December 30, 2023, Henry Schein One, LLC had a net payable balance to Internet Brands of $ 11 million and $ 1 million, respectively, comprised of amounts related to results of operations and the royalty agreement. The components of this payable are recorded within accrued expenses: other within our condensed consolidated balance sheets. We have interests in entities that we account for under the equity accounting method. In our normal course of business, during the three and six months ended June 29, 2024, we recorded net sales of $ 12 million and $ 24 million respectively, to such entities. During the three and six months ended July 1, 2023, we recorded net sales of $ 11 million and $ 23 million respectively, to such entities. During the three and six months ended June 29, 2024, we purchased $ 2 million and $ 5 million respectively, from such entities. During the three and six months ended July 1, 2023, we purchased $ 3 million and $ 5 million respectively, from such entities. At June 29, 2024 and December 30, 2023, we had an aggregate $ 31 million and $ 32 million, respectively, due from our equity affiliates, and $ 5 million and $ 5 million, respectively, due to our equity affiliates. Certain of our facilities related to our acquisitions are leased from employees and minority shareholders. These leases are classified as operating leases and have a remaining lease term ranging from two months to 13 years. As of June 29, 2024, current and non-current liabilities associated with related party operating leases were $ 6 million and $ 22 million, respectively. At June 29, 2024 related party leases represented 7.5 % and 8.6 % of the total current and non-current operating lease liabilities, respectively. At December 30, 2023 related party leases represented 6.3 % and 7.4 % of the total current and non-current operating lease liabilities, respectively.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

Plans of Restructuring and Integration Costs (Tables)	6 Months Ended
Plans of Restructuring and Integration Costs (Tables)	Jun. 29, 2024
Plans of Restructuring [Abstract]
Schedule of Restructuring Costs and Integration Costs	Three Months Ended June 29, 2024 Six Months Ended June 29, 2024 Health Care Distribution Technology and Value- Added Services Total Health Care Distribution Technology and Value- Added Services Total Severance and employee-related costs $ 8 $ 1 $ 9 $ 14 $ 2 $ 16 Accelerated depreciation and amortization 5 - 5 6 - 6 Exit and other related costs 1 - 1 3 - 3 Total restructuring costs $ 14 $ 1 $ 15 $ 23 $ 2 $ 25 Three Months Ended July 1, 2023 Six Months Ended July 1, 2023 Health Care Distribution Technology and Value- Added Services Total Health Care Distribution Technology and Value- Added Services Total Severance and employee-related costs $ 13 $ 1 $ 14 $ 30 $ 4 $ 34 Accelerated depreciation and amortization 2 1 3 9 1 10 Exit and other related costs 1 - 1 2 1 3 Loss on disposal of a business - - - 1 - 1 Total restructuring costs $ 16 $ 2 $ 18 $ 42 $ 6 $ 48
Schedule of Restructuring Reserve by Segment	Technology and Health Care Value-Added Distribution Services Total Balance, December 30, 2023 $ 22 $ 1 $ 23 Restructuring costs 23 2 25 Non-cash accelerated depreciation and amortization (6) - (6) Cash payments and other adjustments (18) (3) (21) Balance, June 29, 2024 $ 21 $ - $ 21

Net Sales from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Disaggregation of Revenue [Abstract]
Net sales	$ 3,136	$ 3,100	$ 6,308	$ 6,160
North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,285	2,262	4,591	4,523
International [Member]
Disaggregation of Revenue [Abstract]
Net sales	851	838	1,717	1,637
Health Care Distribution [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,922	2,907	5,877	5,776
Health Care Distribution [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,099	2,094	4,216	4,189
Health Care Distribution [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	823	813	1,661	1,587
Health Care Distribution [Member] \| Dental [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,924	1,957	3,838	3,855
Health Care Distribution [Member] \| Dental [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,129	1,169	2,232	2,313
Health Care Distribution [Member] \| Dental [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	795	788	1,606	1,542
Health Care Distribution [Member] \| Medical [Member]
Disaggregation of Revenue [Abstract]
Net sales	998	950	2,039	1,921
Health Care Distribution [Member] \| Medical [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	970	925	1,984	1,876
Health Care Distribution [Member] \| Medical [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	28	25	55	45
Technology and Value-Added Services [Member]
Disaggregation of Revenue [Abstract]
Net sales	214	193	431	384
Technology and Value-Added Services [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	186	168	375	334
Technology and Value-Added Services [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	$ 28	$ 25	$ 56	$ 50

- Definition

+ References

+ Details

Fair Value Measurements	6 Months Ended
Fair Value Measurements	Jun. 29, 2024
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 7 – Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows: • Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. • Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. • Level 3— Inputs that are unobservable for the asset or liability. The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values. Investments and notes receivable There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable. Certain of our notes receivable contain variable interest rates. We believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets. Our investments and notes receivable fair value is based on Level 3 inputs within the fair value hierarchy. Debt The fair value of our debt (including bank credit lines, current maturities of long-term debt and long-term debt) is based on Level 3 inputs within the fair value hierarchy, and as of June 29, 2024 and December 30, 2023 was estimated at $ 2,502 million and $ 2,351 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads. Derivative contracts Derivative contracts are valued using quoted market prices and significant other observable inputs. Our derivative instruments primarily include foreign currency forward agreements, forecasted inventory purchase commitments, foreign currency forward contracts, interest rate swaps and total return swaps. The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which are based on market rates for comparable transactions that are classified within Level 2 of the fair value hierarchy. The fair value of the interest rate swap, which is classified within Level 2 of the fair value hierarchy, is determined by comparing our contract rate to a forward market rate as of the valuation date. The fair value of total return swaps is determined by valuing the underlying exchange traded funds of the swap using market-on-close pricing by industry providers as of the valuation date that are classified within Level 2 of the fair value hierarchy. Redeemable noncontrolling interests The values for redeemable noncontrolling interests are based on recent transactions and/or implied multiples of earnings that are classified within Level 3 of the fair value hierarchy. Assets measured on a non-recurring basis at fair value include intangibles. Inputs for measuring intangibles are classified as Level 3 within the fair value hierarchy. The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of June 29, 2024 and December 30, 2023: June 29, 2024 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 8 $ - $ 8 Derivative contracts undesignated - 1 - 1 Total return swap - 1 - 1 Total assets $ - $ 10 $ - $ 10 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 1 - 1 Total liabilities $ - $ 2 $ - $ 2 Redeemable noncontrolling interests $ - $ - $ 856 $ 856 December 30, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 1 - 1 Total return swap - 4 - 4 Total assets $ - $ 6 $ - $ 6 Liabilities: Derivative contracts designated as hedges $ - $ 18 $ - $ 18 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 20 $ - $ 20 Redeemable noncontrolling interests $ - $ - $ 864 $ 864

Income Taxes - Narrative (Details) - USD ($) $ in Millions	6 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023
Income Tax Examination [Line Items]
Effective tax rate	25.20%	22.80%
Tax interest expense (credit)	$ 1	$ 1
Other Liabilities [Member]
Income Tax Examination [Line Items]
Unrecognized tax benefits	107		$ 115
Unrecognized tax benefits that would affect the effective tax rate if recognized	99		107
Total interest	$ 18		$ 16

Redeemable Noncontrolling Interests	6 Months Ended
Redeemable Noncontrolling Interests	Jun. 29, 2024
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontrolling Interests	Note 13 – Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the six months ended June 29, 2024 and the year ended December 30, 2023 are presented in the following table: June 29, December 30, 2024 2023 Balance, beginning of period $ 864 $ 576 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (205) (19) Increase in redeemable noncontrolling interests due to business acquisitions 154 326 Net income (loss) attributable to redeemable noncontrolling interests (1) 6 Distributions declared, net of capital contributions (22) (19) Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests (15) 5 Change in fair value of redeemable securities 81 (11) Balance, end of period $ 856 $ 864

Debt - Private Placement Facilities Narrative (Details) - Private Placement Facilities [Member]	6 Months Ended
	Jun. 29, 2024 USD ($)
Debt Instrument [Line Items]
Number of companies included in private placement facilities	4
Debt instrument maximum borrowing capacity	$ 1,500,000,000
Debt instrument, maturity date	Oct. 20, 2026
Average term of issuances under private placement facilities	12 years
Weighted average interest rate at period end	3.66%
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	15 years

Fair Value Measurements (Tables)	6 Months Ended
Fair Value Measurements (Tables)	Jun. 29, 2024
Fair Value Measurements [Abstract]
Assets and Liabilities Measured and Recognized on a Recurring Basis	June 29, 2024 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 8 $ - $ 8 Derivative contracts undesignated - 1 - 1 Total return swap - 1 - 1 Total assets $ - $ 10 $ - $ 10 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 1 - 1 Total liabilities $ - $ 2 $ - $ 2 Redeemable noncontrolling interests $ - $ - $ 856 $ 856 December 30, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 1 - 1 Total return swap - 4 - 4 Total assets $ - $ 6 $ - $ 6 Liabilities: Derivative contracts designated as hedges $ - $ 18 $ - $ 18 Derivative contracts undesignated - 2 - 2 Total liabilities $ - $ 20 $ - $ 20 Redeemable noncontrolling interests $ - $ - $ 864 $ 864

Segment Data (Details) $ in Millions	3 Months Ended		6 Months Ended
Segment Data (Details) $ in Millions	Jun. 29, 2024 USD ($) countries	Jul. 01, 2023 USD ($)	Jun. 29, 2024 USD ($) segments countries	Jul. 01, 2023 USD ($)
Segment Data [Abstract]
Number of reportable segments \| segments			2
Segment Reporting Information [Line Items]
Net sales	$ 3,136	$ 3,100	$ 6,308	$ 6,160
Operating income	159	201	309	376
Health Care Distribution [Member]
Segment Reporting Information [Line Items]
Net sales	2,922	2,907	5,877	5,776
Operating income	$ 146	166	$ 272	311
Number of countries served globally \| countries	33		33
Health Care Distribution [Member] \| Dental [Member]
Segment Reporting Information [Line Items]
Net sales	$ 1,924	1,957	$ 3,838	3,855
Health Care Distribution [Member] \| Medical [Member]
Segment Reporting Information [Line Items]
Net sales	998	950	2,039	1,921
Technology and Value-Added Services [Member]
Segment Reporting Information [Line Items]
Net sales	214	193	431	384
Operating income	$ 13	$ 35	$ 37	$ 65

Segment Data (Tables)	6 Months Ended
Segment Data (Tables)	Jun. 29, 2024
Segment Data [Abstract]
Business segment information	Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Net sales: Health care distribution (1) Dental $ 1,924 $ 1,957 $ 3,838 $ 3,855 Medical 998 950 2,039 1,921 Total health care distribution 2,922 2,907 5,877 5,776 Technology and value-added services (2) 214 193 431 384 Total $ 3,136 $ 3,100 $ 6,308 $ 6,160 Consists of consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE products, vitamins and orthopedic implants. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services. Three Months Ended Six Months Ended June 29, July 1, June 29, July 1, 2024 2023 2024 2023 Operating Income: Health care distribution $ 146 $ 166 $ 272 $ 311 Technology and value-added services 13 35 37 65 Total $ 159 $ 201 $ 309 $ 376

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
Cash flows from operating activities:
Net income	$ 203	$ 276
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	147	111
Non-cash restructuring charges	6	10
Stock-based compensation expense	20	24
Provision for losses on trade and other accounts receivable	7	2
Benefit from deferred income taxes	(19)	(3)
Equity in earnings of affiliates	(9)	(7)
Distributions from equity affiliates	9	9
Changes in unrecognized tax benefits	3	3
Other	(9)	(9)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	270	18
Inventories	107	163
Other current assets	50	(1)
Accounts payable and accrued expenses	(292)	(295)
Net cash provided by operating activities	493	301
Cash flows from investing activities:
Purchases of property and equipment	(78)	(68)
Payments related to equity investments and business acquisitions, net of cash acquired	(181)	(251)
Proceeds from loan to affiliate	3	3
Capitalized software costs	(20)	(20)
Other	(5)	(4)
Net cash used in investing activities	(281)	(340)
Cash flows from financing activities:
Net change in bank credit lines	242	218
Proceeds from issuance of long-term debt	90	408
Principal payments for long-term debt	(177)	(366)
Proceeds from issuance of stock upon exercise of stock options	2	1
Payments for repurchases and retirement of common stock	(175)	(150)
Payments for taxes related to shares withheld for employee taxes	(8)	(33)
Distributions to noncontrolling shareholders	(28)	(6)
Acquisitions of noncontrolling interests in subsidiaries	(211)	(13)
Net cash provided by (used in) financing activities	(265)	59
Effect of exchange rate changes on cash and cash equivalents	20	0
Net change in cash and cash equivalents	(33)	20
Cash and cash equivalents, beginning of period	171	117
Cash and cash equivalents, end of period	$ 138	$ 137

Stock-Based Compensation (Tables)	6 Months Ended
Stock-Based Compensation (Tables)	Jun. 29, 2024
Stock-Based Compensation [Abstract]
Summary of Stock Option Activity Under the Plans	Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Intrinsic Shares Price Life (in years) Value Outstanding at beginning of period 1,078,459 $ 71.46 Granted - - Exercised (44,750) 62.71 Forfeited (4,608) 84.60 Outstanding at end of period 1,029,101 $ 71.78 7.1 $ 1 Options exercisable at end of period 889,060 $ 69.71
Intrinsic Values	Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Expected to vest 140,041 $ 84.94 7.7 $ -
Status of Unvested RSUs	Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Weighted Average Intrinsic Average Intrinsic Grant Date Fair Value Grant Date Fair Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,655,393 $ 70.34 208,742 $ 78.02 Granted 461,798 75.88 408,681 76.31 Vested (321,460) 62.79 (8,262) 66.53 Forfeited (59,283) 77.31 (35,527) 80.55 Outstanding at end of period 1,736,448 $ 72.99 $ 64.10 573,634 $ 75.78 $ 64.10

Income Taxes	6 Months Ended
Income Taxes	Jun. 29, 2024
Income Taxes [Abstract]
Income Taxes	Note 9 – Income Taxes For the six months ended June 29, 2024 our effective tax rate was 25.2 %, compared to 22.8 % for the prior year period. The difference between our effective tax rate and the federal statutory tax rate primarily relates to state and foreign income taxes. The Organization of Economic Co-Operation and Development (OECD) issued technical and administrative guidance on Pillar Two rules in December 2021, which provides for a global minimum tax rate on the earnings of large multinational businesses on a country-by-country basis. Effective January 1, 2024, the minimum global tax rate is 15% for various jurisdictions pursuant to the Pillar Two rules. As of June 29, 2024, the impact of the Pillar Two rules to our financial statements was immaterial. As we operate in jurisdictions which have adopted Pillar Two, we are continuing to analyze the implications to effectively manage the impact for 2024 and beyond. Future tax reform resulting from these developments may result in changes to long-standing tax principles, which may adversely impact our effective tax rate going forward or result in higher cash tax liabilities. The total amount of unrecognized tax benefits, which are included in “other liabilities” within our condensed consolidated balance sheets, as of June 29, 2024 and December 30, 2023, was $ 107 million and $ 115 million, respectively, of which $ 99 million and $ 107 million, respectively, would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our condensed consolidated statements of income. All tax returns audited by the IRS are officially closed through 2019. The tax years subject to examination by the IRS include years 2020 and forward. In addition, limited positions reported in the 2017 tax year are subject to IRS examination. The amount of tax interest expense included as a component of the provision for taxes was $ 1 million and $ 1 million for the six months ended June 29, 2024 and July 1, 2023, respectively. The total amount of accrued interest is included in “other liabilities,” and was $ 18 million as of June 29, 2024 and $ 16 million as of December 30, 2023. The amount of penalties accrued for during the periods presented was not material to our condensed consolidated financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Stock-Based Compensation - Intrinsic Values (Details) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 29, 2024 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	140,041
Weighted Average Exercise Price \| $ / shares	$ 84.94
Weighted Average Remaining Contractual Life (in years)	7 years 8 months 12 days
Intrinsic Value Per Share \| $	$ 0

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Plans of Restructuring - Schedule of Restructuring Costs and Integration Costs (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 15	$ 18	$ 25	$ 48
Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	9	14	16	34
Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	5	3	6	10
Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1	1	3	3
Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs				1
Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	14	16	23	42
Health Care Distribution [Member] \| Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	8	13	14	30
Health Care Distribution [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	5	2	6	9
Health Care Distribution [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1	1	3	2
Health Care Distribution [Member] \| Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs				1
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1	2	2	6
Technology and Value-Added Services [Member] \| Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 1	1	$ 2	4
Technology and Value-Added Services [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs		$ 1		1
Technology and Value-Added Services [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs				$ 1

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Fair Value Measurements - Assets and Liabilities Measured and Recognized on a Recurring Basis (Details) - USD ($) $ in Millions	Jun. 29, 2024	Dec. 30, 2023	Dec. 31, 2022
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 856	$ 864	$ 576
Fair value, measurements, recurring [Member]
Assets [Abstract]
Total return swaps	1	4
Total assets	10	6
Liabilities [Abstract]
Total liabilities	2	20
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	856	864
Fair value, measurements, recurring [Member] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	8	1
Liabilities [Abstract]
Derivative contracts - liabilities	1	18
Fair value, measurements, recurring [Member] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	1	1
Liabilities [Abstract]
Derivative contracts - liabilities	1	2
Fair value, measurements, recurring [Member] \| Level 1 [Member]
Assets [Abstract]
Total return swaps	0	0
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member]
Assets [Abstract]
Total return swaps	1	4
Total assets	10	6
Liabilities [Abstract]
Total liabilities	2	20
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	8	1
Liabilities [Abstract]
Derivative contracts - liabilities	1	18
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	1	1
Liabilities [Abstract]
Derivative contracts - liabilities	1	2
Fair value, measurements, recurring [Member] \| Level 3 [Member]
Assets [Abstract]
Total return swaps	0	0
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	856	864
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	$ 0	$ 0

Cybersecurity Incident - Narrative (Details) - Cyber Incident [Member] - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Jun. 29, 2024	Jun. 29, 2024
Unusual or Infrequent Item, or Both [Line Items]
Expenses related to cybersecurity incident	$ 3	$ 8
Insurance proceeds related to cybersecurity incident	$ 10	10
Insurance policy limitations		60
Insurance retention		$ 5

Net Sales from Contracts with Customers (Tables)	6 Months Ended
Net Sales from Contracts with Customers (Tables)	Jun. 29, 2024
Net Sales from Contracts with Customers [Abstract]
Disaggregation of Revenue	Three Months Ended Six Months Ended June 29, 2024 June 29, 2024 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,129 $ 795 $ 1,924 $ 2,232 $ 1,606 $ 3,838 Medical 970 28 998 1,984 55 2,039 Total health care distribution 2,099 823 2,922 4,216 1,661 5,877 Technology and value-added services 186 28 214 375 56 431 Total net sales $ 2,285 $ 851 $ 3,136 $ 4,591 $ 1,717 $ 6,308 Three Months Ended Six Months Ended July 1, 2023 July 1, 2023 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,169 $ 788 $ 1,957 $ 2,313 $ 1,542 $ 3,855 Medical 925 25 950 1,876 45 1,921 Total health care distribution 2,094 813 2,907 4,189 1,587 5,776 Technology and value-added services 168 25 193 334 50 384 Total net sales $ 2,262 $ 838 $ 3,100 $ 4,523 $ 1,637 $ 6,160

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
CONDENSED CONSOLIDATED STATEMENTS OF INCOME [Abstract]
Net sales	$ 3,136	$ 3,100	$ 6,308	$ 6,160
Cost of sales	2,118	2,125	4,278	4,219
Gross profit	1,018	975	2,030	1,941
Operating expenses:
Selling, general and administrative	781	707	1,572	1,424
Depreciation and amortization	63	49	124	93
Restructuring costs	15	18	25	48
Operating income	159	201	309	376
Other income (expense):
Interest income	6	3	11	6
Interest expense	(32)	(19)	(62)	(33)
Other, net	(1)	1	1	0
Income before taxes, equity in earnings of affiliates and noncontrolling interests	132	186	259	349
Income taxes	(33)	(41)	(65)	(80)
Equity in earnings of affiliates, net of tax	6	3	9	7
Net income	105	148	203	276
Less: Net income attributable to noncontrolling interests	(1)	(8)	(6)	(15)
Net income attributable to Henry Schein, Inc.	$ 104	$ 140	$ 197	$ 261
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 0.81	$ 1.07	$ 1.53	$ 1.99
Diluted (in dollars per share)	$ 0.80	$ 1.06	$ 1.52	$ 1.97
Weighted-average common shares outstanding:
Basic (in shares)	127,784,380	130,905,899	128,252,628	131,136,450
Diluted (in shares)	128,646,506	131,873,174	129,206,780	132,465,749

Business Acquisitions - Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired (Details) - USD ($) $ in Millions					6 Months Ended	9 Months Ended	12 Months Ended
	Apr. 01, 2024	Oct. 02, 2023	Jul. 05, 2023	Apr. 05, 2023	Jun. 29, 2024	Mar. 30, 2024	Dec. 30, 2023
Identifiable assets acquired and liabilities assumed:
Goodwill					$ 3,905		$ 3,875
TriMed, Inc. [Member]
Acquisition consideration:
Cash	$ 141
Deferred consideration	22
Redeemable noncontrolling interests	153
Total consideration	316
Identifiable assets acquired and liabilities assumed:
Current assets	36
Intangible assets	221
Other noncurrent assets	10
Current liabilities	(9)
Deferred income taxes	(62)
Other noncurrent liabilities	(6)
Total identifiable net assets	190
Goodwill	126
Total net assets acquired	$ 316
Shield Healthcare, Inc. [Member]
Acquisition consideration:
Cash		$ 289			289		286
Deferred consideration		22			22		43
Redeemable noncontrolling interests		37			37		37
Total consideration		$ 348			348		366
Identifiable assets acquired and liabilities assumed:
Current assets					41		41
Intangible assets					166		166
Other noncurrent assets					16		14
Current liabilities					(24)		(24)
Deferred income taxes					(43)		(41)
Other noncurrent liabilities					(7)		(7)
Total identifiable net assets					149		149
Goodwill					199		217
Total net assets acquired					348		366
Shield Healthcare, Inc. [Member] \| Restatement Adjustment [Member]
Acquisition consideration:
Cash					3
Deferred consideration					(21)
Total consideration					(18)
Identifiable assets acquired and liabilities assumed:
Other noncurrent assets					2
Deferred income taxes					(2)
Goodwill					(18)
Total net assets acquired					(18)
S.I.N. Implant System [Member]
Acquisition consideration:
Cash					329		329
Total consideration			$ 329		329		329
Identifiable assets acquired and liabilities assumed:
Current assets					73		67
Intangible assets					87		87
Other noncurrent assets					48		46
Current liabilities					(33)		(33)
Long-term debt					(22)		(22)
Deferred income taxes					(38)		(35)
Other noncurrent liabilities					(27)		(27)
Total identifiable net assets					88		83
Goodwill					241		246
Total net assets acquired					329		$ 329
S.I.N. Implant System [Member] \| Restatement Adjustment [Member]
Identifiable assets acquired and liabilities assumed:
Current assets					6
Other noncurrent assets					2
Deferred income taxes					(3)
Total identifiable net assets					5
Goodwill					(5)
Total net assets acquired					$ 0
Biotech Dental [Member]
Acquisition consideration:
Cash				$ 216		$ 216
Fair value of contributed equity share in a controlled subsidiary				25		25
Redeemable noncontrolling interests				182		182
Total consideration				$ 423		423
Identifiable assets acquired and liabilities assumed:
Current assets						74
Intangible assets						189
Other noncurrent assets						69
Current liabilities						(60)
Long-term debt						(73)
Deferred income taxes						(53)
Other noncurrent liabilities						(20)
Total identifiable net assets						126
Goodwill						297
Total net assets acquired						$ 423

Stock-Based Compensation - Summary of Stock Option Activity under the Plans (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 29, 2024
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	1,078,459
Exercised (in shares)	(44,750)
Forfeited (in shares)	(4,608)
Outstanding at end of period (in shares)	1,029,101
Weighted Average Exercise Price Per Share [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 71.46
Exercised (in dollars per share)	62.71
Forfeited (in dollars per share)	84.60
Outstanding at end of period (in dollars per share)	$ 71.78
Outstanding at end of period, Weighted Average Remaining Contractual Life in Years	7 years 1 month 6 days
Outstanding at end of period, Aggregate Intrinsic Value	$ 1
Options exercisable (in shares)	889,060
Weighted average exercise price, options exercisable (in dollars per share)	$ 69.71

Debt - U.S. Trade Accounts Receivable Securitization Narrative (Details) - U.S. Trade Accounts Receivable Securitization [Member] $ in Millions	6 Months Ended	12 Months Ended
	Jun. 29, 2024 USD ($) number	Dec. 30, 2023 USD ($)
Debt Instrument [Line Items]
Pricing commitment period	3 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Debt instrument maximum borrowing capacity	$ 450
Long-term debt	$ 195	$ 210
Number of banks as agents for debt instrument \| number	2
Minimum [Member]
Debt Instrument [Line Items]
Commitment fee basis points depending upon program utilization	0.0030
Maximum [Member]
Debt Instrument [Line Items]
Commitment fee basis points depending upon program utilization	0.0035
Average Asset Backed Commercial Paper Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate at period end	5.49%	5.67%
Debt instrument, basis spread on variable rate	0.75%	0.75%
Debt instrument, variable rate basis at period end	6.24%	6.42%

Debt - Other Short-Term Bank Credit Lines Narrative (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 29, 2024	Dec. 30, 2023
Line of Credit Facility [Line Items]
Bank credit lines	$ 505	$ 264
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Credit facility borrowing capacity	586	368
Bank credit lines	$ 505	$ 64
Weighted average interest rate on borrowings under credit lines at period end	6.15%	6.02%
Average amount outstanding	$ 263